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ABSTRACT
DNA methyltransferases (DNMTs) play an important
role in establishing and maintaining DNA methyla-
tion. Aberrant expression of DNMTs and their
isoforms has been found in many types of cancer,
and their contribution to aberrant DNA methylation
has been proposed. Here, we generated HEK 293T
cells stably transfected with each of 13 different
DNMTs (DNMT1, two DNMT3A isoforms, nine
DNMT3B isoforms and DNMT3L) and assessed the
DNA methylation changes induced by each DNMT.
We obtained DNA methylation profiles of DNA re-
petitive elements and 1505 CpG sites from 808
cancer-related genes. We found that DNMTs have
specific and overlapping target sites and their DNA
methylation target profiles are a reflection of the
DNMT domains. By examining H3K4me3 and
H3K27me3 modifications in the 808 gene promoter
regions using promoter ChIP-on-chip analysis, we
found that specific de novo DNA methylation
target sites of DNMT3A1 are associated with
H3K4me3 modification that are transcriptionally
active, whereas the specific target sites of
DNMT3B1 are associated with H3K27me3 modifica-
tion that are transcriptionally inactive. Our data
suggest that different DNMT domains are respon-
sible for targeting DNA methylation to specific
regions of the genome, and this targeting might be
associated with histone modifications.
INTRODUCTION
DNA methyltransferases can transfer a methyl group
from S-adenosylmethionine to cytosine at CpG
dinucleotides in mammalian genomes (1). There are
three enzymatically active DNA methyltransferases
(DNMTs), DNMT1, DNMT3A and DNMT3B, in
addition to an enzymatically inactive regulatory factor,
DNMT3L (DNA methyltransferase3-like). Furthermore,
at least two DNMT3A isoforms and more than 20
DNMT3B isoforms have been identiﬁed (2). DNMT1 is
essential for cell survival and mammalian development
(3). It preferentially methylates hemimethylated CpG pal-
indromes in the DNA and is referred to as a ‘maintenance’
DNA methylation enzyme that faithfully copies the DNA
methylation pattern from the parent to the daughter
strand of DNA after replication. DNMT3A and
DNMT3B are structurally similar and play essential
roles in establishing de novo DNA methylation, as well
as maintaining DNA methylation (4). In addition to the
catalytically active DNMTs, DNMT3L plays an import-
ant role in establishing DNA methylation by recruiting or
activating de novo DNMTs (5–7). Although many studies
have shown differential roles for DNMTs in DNA methy-
lation during development, the roles of DNMTs and their
isoforms in aberrant DNA methylation remain to be
studied (4,8).
The causal roles of DNMTs and their isoforms in
aberrant DNA methylation have been studied.
Overexpression of DNMT1 induces hypermethylation of
the imprinted Igf2 gene and leads to its biallelic expression
(9). Overexpression of Dnmt3b1 induces a loss of
imprinting and increases the number of colon tumors in
heterozygous mice carrying a mutant adenomatus
polyposis coli (Apc) tumor suppressor gene (10). Altered
expression levels of DNMT3B have also been observed
during oncogenic transformation induced by SV40T
antigen and activated Ras (11). Overexpression of
the DNMT3B4 isoform, a splice variant of DNA
methyltransferase 3B, is associated with DNA hypo-
methylation in pericentromeric satellite regions and
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nogenesis (12,13). DNMT3B isoforms, which lack the
N-terminal domain of DNMT3B, are predominantly ex-
pressed in non-small cell lung cancer and are associated
with RASSF1A promoter methylation (14–16). The
DNMT3B7 isoform encodes truncated proteins lacking a
catalytic methyltransferase domain and alters both gene
expression and DNA methylation (2). The roles of DNMT
isoforms in gene-speciﬁc DNA methylation have been
studied previously; however, the proﬁling of de novo
DNA methylation target sites for each DNMT isoform
is necessary to understand the role of each DNMT
isoform.
HypermethylationofCpGislandsincancercellsisfound
to be linked to the gain of repressive histone marks, such as
methylation of histone H3 on lysine 9 (H3K9) and lysine
27 (H3K27). H3K9 methylation, a repressive mark, is
associated with hypermethylated genes, and H3K9 di-
and tri-methylation (H3K9me2 and H3K9me3) are found
in hypermethylated genes in embryonic carcinoma cells
(17,18). Cancer-speciﬁc hypermethylated genes are also
packaged with polycomb-mediated H3K27me3 in both
embryonic stem (ES) cells and cancer cells (18–20). The
interaction of EZH2 (Enhancer of Zeste homolog 2),
which is a component of polycomb complex 2/3, with
DNMTs provides a mechanism for crosstalk between the
polycomb complex and DNA methylation (21). Most of
the genes marked with H3K27me3, however, also possess
H3K4me3, which isknown to be ‘bivalent chromatin struc-
ture’ in ES cells (22,23). This bivalent state usually commit
to either H3K4me3 or H3K27me3 during differentiation
(23), suggesting that both H3K4me3 and H3K27me3
marked regions in somatic cells might be vulnerable to
the aberrant DNA methylation observed in cancer cells.
The mechanism of how these different histone marked
genes become methylated in cancer, however, is not clear.
In this study, we successfully identiﬁed de novo DNA
methylation target sites of speciﬁc DNMTs for the ﬁrst
time by mimicking cancer cell overexpression of
DNMTs. Furthermore, we characterized the relationship
of histone modiﬁcations at de novo DNA methylation
target sites of DNMTs in 808 cancer-related genes.
MATERIALS AND METHODS
DNA methyltransferase isoform constructs
pIRESpuro3 vector (Clontech), a stable integrating
plasmid, was modiﬁed by ligating a myc epitope tag se-
quence (forward 50-CTAGCCCACCATGGAGCAGAA
GCTGATCTCAG-AGGAGGACCTGG-30 and reverse
50-AATTCCAG-GTCCTCCTCTGAGATCAG-CTTCT
GCTCCATGGTGGG-30) to the NheI-EcoRI sites of the
pIRESpuro3 vector. pcDNA3/Myc-human DNMT1,
DNMT3A1, DNMT3A2, DNMT3B1, DNMT3B2,
DNMT3B3 and DNMT3L constructs were kindly
provided by Dr. Arthur D. Riggs from the City of Hope
Cancer Center (24). These DNMTs were subcloned into
the EcoR1–NotI sites of the pIRESpuro/Myc vector
to facilitate selection of functional clones stably
overexpressing the N-terminal myc-tagged DNMT
isoforms. The C-terminus of DNMT3B4 was ampliﬁed
from a pcDNA/Myc DNMT3B2 construct using Pfu
Taq polymerase (Stratagene) with primers (forward
50-TGGGTCCAGTGGTTTGGCGATG-30 and reverse
50-GAGCGGCCGCTTAACTGTTCA-TCCCGGGTA
GG-30) and ligated into the BstXI–NotI sites of the
pIRESpuro/Myc DNMT3B2 vector. The C-terminus of
the DNMT3B5 isoform was ampliﬁed with primers
(forward 50-AACTCGAGCTGCAGGACTGCTTGGAA
TACAATAGGA-TAGCCAAGGATCTTTGGCTTTCC
TGTGC-30 and reverse 50-TTCTCGAGCTATT-CACAT
GCAAAGTAGTC-30), ligated to the XhoI site of
pcDNA3/Myc DNMT 3B2, and subcloned into the
pIRESpuro/Myc vector. Human DNMT3B1or
DNMT3B2 cDNA was ampliﬁed from pcDNA3/
Myc-DNMT 3B1 with primers (forward; 50-TCGAATTC
ATGGAGTCCCCGCAGGTGGAG-30 and reverse; 50-C
ATCGCCAA-ACCACTGGACCCA-30) and ligated into
the EcoRI–BstX1 sites of pIRESpuro/Myc-DNMT3B1
or DNMT3B2, respectively. To generate DNMT3B3
and DNMT3B4, the N-terminal sequence of
DNMT3B3 was ampliﬁed with primers (forward; 50-C
GAATTCATGGAGTCCCCGCAGGTGGAGGCAGA
CAGTGGAGATGGAGACAGTTCAGAGTATCAGG
TCTCTGC-30 and reverse; 50-CTTTCTCCAGAGCATG
GTAC-30) from a DNMT3B3 cDNA, which was
ampliﬁed from HCT 116 cDNA using RT-PCR and
ligated into the EcoRI–MscI sites of IRESpuro/Myc-
DNMT3B1 or DNMT3B2, respectively.
Generation of stable cell lines overexpressing DNA
methyltransferases
Expression vectors encoding N-terminal myc-tagged
DNMT isoforms were transfected into HEK 293T cells
using Lipofectamine
TM 2000 (Invitrogen), and cells were
subsequently selected in medium containing Dulbecco’s
modiEed Eagle’s medium (DMEM), 10% fetal bovine
serum, 1% penicillin/streptomycin and 3ug/ml puromycin
(Clontech) for 30 days. Two independent polyclonal cell
lines, indicated as cell line 1 and cell line 2, were estab-
lished by performing two independent transfection and se-
lection experiments. Cell line 1 was subjected to Illumina
DNA methylation analysis and mRNA expression micro-
array analysis. Both cell line 1 and cell line 2 were sub-
jected to bisulﬁte PCR pyrosequencing analysis.
mRNA expression by quantitative real time polymerase
chain reaction
Total RNA was extracted from puromycin-resistant poly-
clonal cells stably transfected with DNMT isoforms using
the RNeasy Mini kit (Qiagen). Reverse transcription was
performed using a ﬁrst strand cDNA synthesis kit (NEB),
according to the manufacturer’s recommended protocol.
To quantify mRNA expression, real-time polymerase
chain reaction (PCR) was performed with Brilliant
SYBR Green QPCR Master Mix, according to the manu-
facturer’s instructions (Stratagene). For each sample, an
RT reaction under the same conditions but without
reverse transcriptase was used as a negative control. All
data were converted to relative values based on a standard
Nucleic AcidsResearch, 2011, Vol.39,No. 1 105curve and normalized to the glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) values obtained for the same
sample. All primers are listed in Supplementary Table S1.
Illumina mRNA expression microarray
mRNA expression microarray experiments were per-
formed using a whole-genome expression array (Sentrix
Human-6 Expression BeadChip version 3, Illumina) at
the University of Southern California Epigenome Center.
This array chip consists of about 48000 probe sequences
derived from RefSeq genes and the latest Unigene release
(http://www.switchtoi.com/annotationﬁles.ilmn). Data
were analyzed using the BeadStudio software provided by
Illumina.
Protein expression of DNA methyltransferases
The level of ectopically expressed DNMT isoforms was
examined by immunoblotting. Brieﬂy, whole-cell extracts
from puromycin-resistant polyclonal cell line 1 stably ex-
pressing DNMT isoforms were prepared using 2xSDS
sample buffer (Bio-Rad). After boiling, cell extracts were
separated in 6% and 8% SDS-PAGE gels and transferred
onto PVDF membranes (GE Healthcare). DNMT
isoforms were detected using an anti-Myc antibody
(Invitrogen), and the level of GAPDH in the same
samples was determined using an anti-GAPDH antibody
(Research Diagnostics Inc.) as a loading control.
Alternatively, the percentage of cells overexpressing
DNMT proteins was assessed by immunocytochemistry,
comparing anti-Myc antibody staining and DAPI staining
(Supplementart Figure S3).
DNA methylation measurements by bisulﬁte PCR
pyrosequencing
DNA from cell lines was extracted as described previously
(25). Sodium bisulﬁte conversion of genomic DNA was
performed using the EZ DNA Methylation-Gold Kit
TM
(Zymo Research), according to the manufacturer’s recom-
mended protocol. All DNA repetitive elements, including
LINE1, Alu Yb8, Sat-a and NBL2 were measured in du-
plicate, as described previously (26,27). For validation of
the Illumina DNA methylation data, DNA methylation at
the same CpG site measured by the Illumina DNA methy-
lation assay was quantitatively assessed by measuring the
ratio of unmethylated CpG to methylated CpG using
bisulﬁte PCR pyrosequencing (28). All primers used for
bisulﬁte PCR and pyrosequencing primers are listed in
Supplementary Table S1. DNA from HEK 293T cells
treated with 5-aza-20-deoxycytidine (DAC)- or
M.SssI-treated DNA was used as a decreased or fully
methylated control, respectively, for bisulﬁte
PCR pyrosequencing. DAC-treated DNA was extracted
from HEK 293T cells treated with DAC daily for
3 days. M.SssI-treated DNA was obtained as described
previously (29).
Illumina DNA methylation analysis
The Illumina GoldenGate Methylation Cancer Panel I was
used to measure de novo DNA methylation induced by
each DNMT isoform. The Illumina DNA methylation
assay was performed on sodium bisulﬁte-converted
DNA from cell line 1 overexpressing each DNMT
isoform by the University of Southern California
Epigenome Center. Sodium bisulﬁte conversion for the
Illumina assay was performed using the EZ-96 DNA
Methylation Kit (Zymo Research). Illumina GoldenGate
methods and reagents have been previously described (30).
In brief, this assay employs ﬂuorescently tagged competi-
tive primers to amplify methylated (red) or unmethylated
(green) alleles at speciﬁc CpG sites. The ratio of these
competitive PCR primers is scored as a  -value that cor-
relates with the level of DNA methylation (30). In total,
1505 CpG sites from 808 genes are interrogated for DNA
methylation using the Illumina GoldenGate Methylation
Cancer Panel I (Illumina, GM-17-211) (31). All informa-
tion from the 1505 loci is listed in Supplementary Table
S2. The 1505 sequences on the GoldenGate Methylation
Cancer Panel I are fully described at www.illumina.com.
Hierarchical cluster analysis of the 1505 loci was per-
formed using the software at www.discover.nci.nih.
gov/cimminer/, and the average linkage and Euclidean
distance were used in the hierarchical clustering algorithm.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) assays were per-
formed largely as described previously (32). In brief, HEK
293T cells were grown in 150-mm dishes to 90% conﬂu-
ence. Cells were ﬁxed with 1% formaldehyde for 10min
and sonicated to an average DNA size of 200–1000bp in
nuclear lysis buffer. Lysates were diluted 10 times with the
dilution buffer and pre-cleared with 30ml of a mixture of
salmon sperm DNA–protein A agarose slurry (Upstate
Biotechnology) to reduce non-speciﬁc background.
Immunoprecipitation was conducted with normal rabbit
IgG (Santa Cruz Biotechnology, sc-2027), anti-H3K4me3
(Abcam, ab8580), anti-H3K9me3 (Abcam, ab8898) or
anti-H3K27me3 (Upstate, 07-449) with rotation overnight
at 4 C. We added 50ml of protein A-agarose (Upstate
Biotechnology) to the lysates for 2h, and then washed
one time each with low salt wash buffer (150mM NaCl),
high salt wash buffer (300mM NaCl), and LiCl wash
buffer, followed by two times with TE buffer. The
immunoprecipitated DNA was puriﬁed using a PCR puri-
ﬁcation kit (Qiagen) and quantiﬁed by qPCR using
Brilliant SYBR Green QPCR Master Mix or
FullVelocity
TM SYBR Green QPCR Master Mix accord-
ing to the manufacturer’s instructions (Stratagene). All
data were converted to relative values based on a
standard curve and normalized to 1% input values of
the same sample. All primers are listed in Supplementary
Table S1.
ChIP-on-chip assay
ChIP DNA was ampliﬁed using the WGA2 Kit (Sigma),
according to manufacturer’s recommended protocol.
Labeling of ChIP DNA and input, hybridization to
NimbleGen 385K RefSeq promoter arrays, and scanning
were performed using NimbleGen protocols in their
service laboratory in Iceland. To detect the peaks for
106 Nucleic Acids Research, 2011,Vol. 39,No. 1histone modiﬁcation, the data were processed using a false
discovery rate (FDR<0.2) by NimbleGen (www
.nimblegen.com).
RESULTS
Generation of cell lines stably expressing DNMT isoforms
We established cell lines that stably express each of 13 dif-
ferent DNMTs in HEK 293T cells. Endogenous expres-
sion of these DNMTs, except DNMT3A2, was detected in
HEK 293T cells, as shown in Supplementary Figure S1.
At 30 days post-transfection, we were able to obtain poly-
clonal cells stably expressing various levels of different
DNMTs (Figure 1A). The level of ectopically
overexpressed DNMTs was compared with the endogen-
ous expression of DNMT using real-time RT-PCR
(Supplementary Figure S2). We examined the ectopic
mRNA expression of each DNMT by real time
RT-PCR of the IRES (internal ribosomal entry site),
which is transcribed with DNMT (Figure 1B). We found
that different DNMTs and their isoforms are expressed at
similar levels in two different polyclonal cells by independ-
ent transfection experiments. We also conﬁrmed the
protein expression levels of DNMTs and their isoforms
using immunoblotting with a myc antibody (Figure 1C).
In contrast to mRNA expression, the protein expression
levels of DNMTs varied. Although it is not completely
clear, differences in protein expression levels might be
attributable to differences in the stability of the
DNMT3B isoforms. We compared the level of endogen-
ous and exogenous DNMT1 and DNMT3A1 proteins
(Supplementary Figure S1-C). For DNMT3B1, we could
detect exogenous DNMT3B1 but not the endogenous
DNMT3B1, possibly due to low endogenous expression,
as seen in Supplementary Figure S1-A. Importantly, we
later found that the protein expression levels of different
DNMTs were not correlated with the DNA methylation
changes shown in Figure 3A. Finally, the transfection ef-
ﬁciency was conﬁrmed using immunocytochemistry with a
myc antibody (Supplementary Figure S3). Protein expres-
sion levels obtained by immunocytochemistry were con-
cordant with the immunoblotting results and showed that
all cells express each DNMT. Therefore, the transfection
efﬁciency of different DNMTs did not inﬂuence the level
of DNA methylation changes detected later.
DNA methylation of repetitive elements induced by
DNMT isoforms
DNA methylation of repetitive elements can be unequally
restored by different DNMTs in mouse ES cells (8),
raising the possibility that different DNMTs and their
isoforms may play distinct roles in methylating different
types of repetitive elements in somatic cells as well. To
investigate whether different DNMTs could change the
DNA methylation of different repetitive elements, we
measured the DNA methylation of both interspersed
DNA repeats and tandem repeats using a previously
described bisulﬁte PCR pyrosequencing assay (27)
(Figure 2). Interspersed DNA repeats can act as a surro-
gate for global DNA methylation changes through the
analysis of the methylation of a pool of repetitive
elements dispersed throughout the genome. LINE1, a sub-
family of LINEs (Long Interspersed Nuclear Elements), is
relatively hypomethylated in HEK 293T cells compared to
normal tissues (76%, data not shown); its methylation
was increased by DNMT3B1, DNMT3B2 and
DNMT3B isoforms, but not de novo DNMT3A
isoforms (Figure 2A, left). Another interspersed repeat,
AluYb8, a subfamily of SINEs (Short Interspersed
Nuclear Elements), did not change its DNA methylation
levels signiﬁcantly with the expression of any isoform.
Methylation levels of this element, however, were high
to begin with, and this may reﬂect a technical limitation
of our AluYb8 assay (Figure 2A, right).
We also measured DNA methylation of Sat-a and
NBL-2 tandem repeats. Satellite-a (Sat-a) repeats are
known to be hypomethylated in cancer and NBL-2
repeats are known to be hypomethylated in ICF
(Immunodeﬁciency, Centromeric instability and Facial
abnormalities) syndrome patients who have a germline
mutation of DNMT3B. Tandem repeats showed similar,
but slightly different, results than the interspersed repeats
(Figure 2B). Both DNMT3A and DNMT3B isoforms
could increase the DNA methylation of Sat-a, but
DNMT3B isoforms (except the catalytically inactive
forms) were more efﬁcient in methylating Sat-a repeats.
As expected, the maintenance form of the enzyme,
DNMT1, in addition to the catalytically inactive
DNMT3B isoforms (DNMT3B3, DNMT3B4 and
DNMT3B5) and DNMT3L did not change the methyla-
tion level of all DNA repeats studied. The role of
DNMT3B3 in DNA methylation is controversial.
In vitro assays have shown that DNMT3B3 puriﬁed
from mammalian cells has the same DNA methylation
activity as DNMT3B1 (11), but DNMT3B3 in vivo does
not affect episome DNA methylation (24). Our data are
consistent with the latter ﬁnding and support the idea
DNMT3B3 might be an inactive DNMT, with impair-
ment of its methyltransferase catalytic motifs VIII and
IX (33). Overexpression of DNMT3B4 has been suggested
to lead to hypomethylation of pericentromeric satellite
regions in human hepatocellular carcinoma (13).
According to our data, however, cells with overexpressed
DNMT3B4 showed no methylation changes in the DNA
repeats studied. The results of two independent stable
transfection experiments showed consistent DNA methy-
lation changes for all four different repetitive elements;
thus, different DNMTs and their isoforms are responsible
for the methylation of different DNA repetitive elements.
High-throughput gene-speciﬁc DNA methylation analysis
To identify multiple target sites of different DNMTs and
their isoforms in the human genome, we studied the
methylation of speciﬁc gene promoters using the
Illumina GoldenGate Cancer Methylation Panel I, which
evaluates the methylation status at 1505 CpG sites of
808 gene promoters. A one-dimensional supervised
cluster analysis of all 1505 loci using correlation to
measure the distance between loci illustrates groups of
genes that are de novo methylated by each DNMT
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Figure 1. Generation of cell lines stably overexpressing DNA methyltransferases (DNMTs). (A) Schematic structure of DNMT isoforms and
expression vector constructs. The conserved PWWP and PHD-like domains, DNMT catalytic motifs (I, IV, VI, IX and X), and alternative
splicing sites are indicated. The coding regions of DNMT 3B4 and DNMT 3B5 in red represent frame shift mutations generated by alternative
splicing. The expression vectors encode N-terminal myc-tagged DNMT isoforms. (B) mRNA expression of exogenous DNMTs. mRNA expression of
each DNMT isoform was assessed by real time RT-PCR with primers designed for the IRES region located on a bicistronic transcript and
normalized to the expression of GAPDH. (C) Protein expression levels of exogenous DNMT isoforms by western blotting using a myc antibody.
The expression level of DNMTs shown in the right panel was lower than those in the left panel, such that a 10-fold higher amount of protein was
loaded in the left panel, as shown by the GAPDH control. Note the 10-fold higher amount of DNMT 3A1 in the left panel was compared with 3A1
(1/10) in the right panel.
108 Nucleic Acids Research, 2011,Vol. 39,No. 1isoform (Figure 3A and Supplementary Table S2). Four
de novo methylation sites detected by the Illumina DNA
methylation assay were randomly selected, and the methy-
lation changes at these loci were validated using bisulﬁte
PCR pyrosequencing, a more precise and quantitative
way to assess DNA methylation (Figure 3B and
Supplementary Figure S4). DNA methylation, as
determined by the Illumina DNA methylation assay,
was highly concordant with the methylation status
determined by bisulﬁte PCR pyrosequencing for the four
selected loci in 15 different groups, with the Spearman’s
rank correlation coefﬁcient rs=0.71 (P<0.0001).
These results conﬁrmed the overall validity of the
Illumina DNA methylation assay. In addition, two inde-
pendent transfection experiments (cell line 1 and cell line
2) resulted in the same methylation levels, conﬁrming that
DNA methylation induced by different DNMTs is not a
stochastic event and is independent of clonal selection.
In the Illumina DNA methylation assay, the level of
DNA methylation was expressed as a  -value, ranging
from 0 (unmethylated sites) to 1 (methylated sites) (30).
To determine the loci with changed DNA methylation
status induced by DNMTs and their isoforms, we used
the absolute difference in  -value (| |>0.1843) with
two-sided 99% conﬁdence intervals between the
non-transfected and the mock vector-transfected HEK
293T control groups (R
2=0.98). This difference in
 -value is comparable to a value previously described as
the technical variability of the assay (30). At a change in
 >0.1843, we found that different DNMTs and
their isoforms change a variable number of CpG sites
(Figure 4A). Overexpression of DNMT3A and
DNMT3B isoforms increased DNA methylation at
153–377 loci and both CpG islands and non-CpG
islands were hypermethylated. As expected, the catalytic-
ally inactive DNMT3B3, 3B4 and 3B5 isoforms did
not change the DNA methylation. Interestingly,
DNMT1 (36 loci) and DNMT3L (42 loci) induced
hypermethylation at a relatively small number of sites
compared to the de novo DNMT3A and DNMT3B
isoforms, suggesting that DNMT1 and DNMT3L might
play a regulatory role in DNA methylation at certain CpG
sites through cooperation with endogenous de novo
DNMTs (24).
B
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Figure 2. DNA methylation changes of DNA repetitive elements induced by DNMT isoforms. (A) DNA methylation changes of two interspersed
DNA repeats, LINE1 and AluYb8. (B) DNA methylation changes of two tandem repeats, Sat-a and NBL-2. DNA methylation in HEK 293T cells
treated with 5-aza-20-deoxycytidine, a DNA methylation inhibitor (decreased methylation control), or M.SssI, a CpG methyltransferase (fully
methylated control), is shown as 293T/DAC or 293T/M.SssI, respectively. Two independent transfection experiments are indicated as cell line 1
and cell line 2.
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To identify speciﬁc and overlapping target sites of
DNMTs, 514 de novo methylated sites ( -value in-
crease>0.1843) for any of DNMTs were used in cluster
analysis (Figure 4B). Among 514 loci, 304 loci that were
not methylated or only slightly methylated in HEK 293T
cells ( -value<0.1843) became methylated exclusively in a
subset of DNMT-overexpressing cells. In addition, 210
loci that were already methylated to some extent in
HEK 293T cells ( -value 0.1843) became heavily
methylated by a subset of DNMTs. Two-dimensional un-
supervised hierarchical cluster analysis showed a
A
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Figure 3. Gene-speciﬁc DNA methylation changes induced by DNMT isoforms. (A) Illumina DNA methylation assay for gene-speciﬁc DNA
methylation. DNA methylation proﬁles were one-dimensionally clustered by methylation level at 1505 loci based on the  -value. The  -value, a
continuous measure of DNA methylation levels, is represented in colors ranging from green ( -value 0, unmethylated sites) to red ( -value 1,
methylated sites) (30). Each column represents 1 of 1505 CpG sites, and each row represents the DNA methylation proﬁle from a stably transfected
cell line that expresses each of the different DNMTs indicated on the left. The relatedness of the DNA methylation patterns is represented by a tree
(top), with the lengths of the branches representing the degree of similarity based on the average linkage and Euclidean distance. 293T/M.SssI and
293T/WGA (whole genome ampliﬁcation) were used as methylated and unmethylated controls. (B) Validation of the Illumina DNA methylation
assay using bisulﬁte PCR pyrosequencing. Absolute DNA methylation at the EYA4_P794_F and HOXA5_P479_F loci was directly measured by
bisulﬁte PCR pyrosequencing and compared with the percent methylation extrapolated from the  -value in Illumina DNA methylation assay.
Two independent stable transfection experiments are indicated as cell line 1 and cell line 2.
110 Nucleic Acids Research, 2011,Vol. 39,No. 1correlation of DNA methylation proﬁles induced by struc-
turally similar DNMTs rather than by the level of DNMT
expression, as shown in Figure 1C. We compared the spe-
ciﬁc and overlapping target sites of pairs of DNMTs that
were closely clustered. With regard to DNA methylation
target sites, DNMT3A1 overlapped with DNMT3A2 by
93%; DNMT3B1 overlapped with DNMT3B2 by 93%;
DNMT3B1 overlapped with DNMT3B2 by 87%;
and DNMT3B3 overlapped with DNMT3B4 by
83%. DNMT3A1 and DNMT3B1, which showed the
most distinct methylation pattern, made up 90.8% of all
514 de novo methylated loci. The 514 de novo methylated
loci corresponded to 397 gene promoter regions, as indi-
vidual CpG sites were grouped into gene promoter
regions. We next compared speciﬁc and overlapping
target gene promoter regions for DNMT3A1 and
DNMT3B1. The DNMT3A1 target genes overlapped
with the DNMT3B1 target genes in 195 gene promoter
A
B
Figure 4. Distribution of CpG islands and histone marks at loci with changes in DNA methylation. (A) Distribution of CpG islands (black) and
non-CpG islands (white) at hyper- and hypomethylated loci induced by each DNMT isoform. Hyper-and hypomethylated CpG sites induced by each
DNMT were selected by an absolute difference in the beta value (| |-value>0.1843). DNMT1 equally induced hyper and hypomethylated loci.
Most isoforms induced exclusively hypermethylation at both CpG islands and non-CpG islands, except 3B3, 3B4 and 3B5, which are known to be
catalytically inactive. (B) Unsupervised two-dimensional clustering analysis with all 514 de novo methylated loci induced by any DNMT isoform
shows that de novo DNA methylation proﬁles induced by DNMT isoforms were clustered according to the structural similarity of the DNMT
isoforms.
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DNMT3B1 had 78 speciﬁc target genes (Figure 5A).
Association between DNA methylation and histone
modiﬁcations
To understand the characteristics of the speciﬁc and
overlapping target genes for DNMT3Al and
DNMT3B1, we studied the association between de novo
methylated genes and histone modiﬁcations in HEK 293T
cells (Figure 5B). We examined H3K4me3 and H3K27me3
modiﬁcations of all known well-characterized RefSeq
genes using promoter ChIP-on-chip experiments. ChIP
DNA for H3K4me3 and H3K27me3 was hybridized to
NimbleGen 385K RefSeq promoter arrays. We identiﬁed
an initial list of 8527 and 3133 genomic regions for
H3K4me3 and for H3K27me3, respectively, from 2.2kb
upstream to 0.5kb downstream of the transcription start
sites (Supplementary Tables S3 and S4). By cross-
application analysis between the ChIP-on-chip and
Illumina DNA methylation assays, we identiﬁed histone
modiﬁcations of 808 of the genes studied for DNA methy-
lation analysis (Figure 5B and Supplementary Table S5).
The overlapping genes between DNMT3A1 and
DNMT3B1 had no preference for histone marks;
however, we found that speciﬁc target genes of
DNMT3A1 were associated with H3K4me3 modiﬁcation
(P=4 10
 5), while speciﬁc target genes of DNMT3B1
were associated with H3K27me3 modiﬁcation
(P=9 10
 9). To validate the ChIP-on-chip data, as
well as the association between histone modiﬁcation and
DNA methylation, we performed ChIP combined with
real-time PCR for the 20 gene promoter regions that
showed the greatest increase in de novo DNA methylation
speciﬁc for DNMT3A1 and for DNMT3B1 (Figure 5C).
By comparing the ChIP-on-chip data to the ChIP data for
these 20 genes, we found that histone modiﬁcations were
concordant between the two assays at 17 of the 20 gene
promoter regions. In the ChIP experiment, we detected
histone modiﬁcations at three gene promoter regions
(DDR1; H3K4me3, RAN; H3K4me3 and IGF2AS;
H3K27me3) for which histone modiﬁcations were not
detected in the ChIP-on-chip experiment. In the ChIP ex-
periment, all speciﬁc DNMT3A1 target genes were
marked by H3K4me3; whereas speciﬁc DNMT3B1
target genes were marked with H3K27me3 and/or
H3K9me3. These data demonstrated that speciﬁc target
sites of DNMT3A1 and DNMT3B1 are associated with
active (H3K4me3) and repressive histone modiﬁcations
(H3K27me3 and H3K9me3), respectively.
Changes in mRNA expression and histone modiﬁcation
by DNMTs
To examine the different effects of DNMT3A1 and
DNMT3B1 on gene expression, we have conducted ex-
pression array using the Illumina mRNA expression
array (HumanWG-6 v3.0 containing 38276 transcripts)
(Figure 6A). Genes with expression levels that were
downregulated more than 2-fold with two-sided 99.9%
conﬁdence intervals between HEK 293T cells and
mock vector-transfected cells were selected (R
2=0.99).
We found that 1314 genes (3.4%) were downregulated in
DNMT3A1-overexpressing cells compared to parent cells;
whereas a relatively small number of 101 genes (0.26%)
was downregulated in DNMT3B1-overexpressing cells,
which is comparable to the 49 genes (0.12%)
downregulated in catalytically inactive DNMT3B4-
overexpressing cells. The same pattern of mRNA
downregulation by DNMT3A1 and DNMT3B1 was
exhibited in the analysis of 808 genes studied for
DNA methylation (Figure 6B). We also found that
histone modiﬁcations are tightly associated with transcrip-
tion activity of genes as previously reported (23)
(Supplementary Figure S5). Thus, these data suggest
that DNMT3A1 can methylate genes that are transcrip-
tionally active with H3K4me3, while DNMT3B1 can
methylate genes that are silenced by repressive histone
modiﬁcations (H3K27me3/H3K9me3). Furthermore, we
examined whether this gene repression was coupled to
histone modiﬁcation changes by performing qRT-PCR
to evaluate mRNA expression and ChIP experiments to
determine the levels of H3K4me3, H3K9me3 and
H3K27me3 for DNMT3A1- and DNMT3B1-speciﬁc
target genes. From the mRNA expression microarray
data, we chose EYA4 and HOXA11, which showed both
increased DNA methylation and gene downregulation, as
DNMT3A1-speciﬁc target genes. We found that the basal
expression levels of DNMT3A1 target genes (EYA4 and
HOXA11) were relatively higher than those of DNMT3B1
target genes (IGF2AS and CDH11), which is consistent
with the histone modiﬁcations of these genes (Figure 6C).
The mRNA expression of the DNMT3A1 target genes
was signiﬁcantly decreased in DNMT3Al overexpressed
cells, whereas DNMT3B1 target gene expression at
baseline was too low to measure decreases in
DNMT3B1 overexpressed cells. However, H3K4me3 was
slightly decreased or remained unchanged in DNMT3A1
or DNMT3B1 overexpressed cells, compared to
HEK293T cells. We also did not see signiﬁcant changes
in the repressive histone marks, H3K27me3 and
H3K9me3 in DNMT3A1 or DNMT3B1 overexpressed
cells (Supplementary Figure S6).
The roles of DNMT domains in targeting
DNMT isoforms
Clustering analysis showed that DNA methylation proﬁles
were dependent on the structural similarity of DNMT
isoforms in Figure 4B, suggesting a functional role of
DNMT domains in targeting DNMT isoforms to
speciﬁc sites. To study the role of each domain, we dis-
sected DNMT isoforms by directly comparing isoforms
that contained or lacked speciﬁc domains. The de novo
methylated sites of DNMT isoforms that contained
speciﬁc domains were directly compared to the de novo
methylated gene promoter regions of DNMT isoforms
that were identical, with the exception that they lacked
the speciﬁc domain of interest (Figure 7 and
Supplementary Table S6). DNMT3B exon10, which is
commonly removed from some DNMT3B isoforms,
seemed to be important for de novo DNA methylation,
given that overexpression of DNMT3B2 and DNMT
112 Nucleic Acids Research, 2011,Vol. 39,No. 1A
C
B
Figure 5. Histone modiﬁcations of DNMT3A1- and DNMT3B1-speciﬁc target genes. (A) The Venn diagram depicts the number of speciﬁc and
overlapping target gene promoter regions between DNMT3A1 and DNMT3B1. DNMT3A1 and DNMT3B1 have 195 overlapping target genes.
DNMT3A1 has 71 speciﬁc target genes, and DNMT3B1 has 78 speciﬁc target genes. (B) The association between DNMT target genes and histone
modiﬁcations. Cross-application analysis between DNA methylation measurement and ChIP-on-chip analysis of histone modiﬁcations (H3K4me3
Continued
Nucleic AcidsResearch, 2011, Vol.39,No. 1 1133B2, which lack this exon, led to fewer de novo DNA
methylation sites than did the overexpression of their
counterparts (Figure 7A). The PWWP domain of
DNMT3B is known to play an important role in DNA
binding (34), and our results support this role given that
the lack of the PWWP domain led to fewer de novo methy-
lation events compared to when this domain was present
(Figure 7B). Interestingly, the N-terminal domain
appeared to play different roles in DNMT3A and
DNMT3B. Overexpression of the DNMT3A2 isoform,
which lacks 220 N-terminal amino acids of DNMT3A1,
led to the de novo methylation of 29 fewer genes (+15
genes and  44 genes) than did overexpression of
DNMT3A1. Conversely, the loss of 199 amino acids
from the DNMT3B1 N-terminal domain, which deﬁnes
the delta forms of the DNMT3B isoforms, led to a
greater number of de novo methylation sites than did its
counterparts (Figure 7C).
The loss of each domain led to changes in DNMT tar-
geting for histone modiﬁcation (Figure 7). The lack of
DNMT3B exon 10 was associated with a decrease in the
preference for H3K27me, but the lack of the PWWP
domain was related to a decrease in the preference for
H3K4me. The loss of the DNMT3A1 N-terminus was
associated with a decrease in the preference for
H3K27me, while the loss of the DNMT3B1 N-terminus
was associated with an increase in the preference for
H3K4me3. These results suggest that speciﬁc domains
can play a role in targeting DNMT isoforms to speciﬁc
genomic sites and that this targeting may be related to
speciﬁc histone modiﬁcations.
DISCUSSION
While there are numerous studies on DNA
methyltransferase enzymes, the target sites of individual
DNMT enzymes are poorly understood due to the lack
of an efﬁcient cell model system. We generated a cell
model system that overexpresses each of 13 different
DNMTs and comprehensively identiﬁed the de novo
methylation sites. Overexpression of catalytically active
DNMT3A and DNMT3B isoforms increased de novo
DNA methylation, but inactive forms of DNMT3B
could not increase DNA methylation. In addition,
DNMT1 and DNMT3L induced hypermethylation at a
relatively small number of sites compared to isoforms of
DNMT3A and DNMT3B, as might be expected. We
found that de novo DNA methylation induced by different
DNMTs was tightly related to the structure of DNMTs
and that their speciﬁc target sites were associated with
speciﬁc histone modiﬁcations.
Here, we propose a possible mechanism by which
de novo DNA methylation is targeted to different DNA
sites in somatic cells (Supplementary Figure S7). By
studying the association between unique de novo
methylated sites of each DNMT isoform with speciﬁc
histone modiﬁcations, we found that DNMT3A1 was
preferentially targeted to H3K4me3-marked genes, while
DNMT3B1 was preferentially targeted to H3K27me3-
and/or H3K9me3-marked genes. Previous studies have
shown a relationship between DNA methylation and
H3K4me3 and H3K27me3. The polycomb repressor
complexes can directly recruit de novo methyltransferases
to H3K27me3-marked genes and lead to speciﬁc gene
hypermethylation (21). Furthermore, recent genome-wide
mapping of histone modiﬁcations indicates that bivalent
histone marks (H3K4me3/H3K27me3) are more wide-
spread than H3K27me3 alone in ES cells (22).
Therefore, frequently hypermethylated genes in malignant
cells are signiﬁcantly enriched with regard to ‘bivalent
chromatin structure’ in ES cells, which are usually
committed to either H3K4me3 or H3K27me3 in somatic
cells, suggesting that not only H3K27me3-marked genes,
but also H3K4me3-marked genes, can be methylated in
cancer cells. Kondo et al. (35) also showed that the
majority of gene silencing induced by DNA hyper-
methylation in prostate cancer is independent of
polycomb-mediated gene silencing, suggesting that the
majority of gene silencing caused by DNA hyper-
methylation in cancer might occur via a mechanism
involving more than the polycomb repressive complex. It
is not clear, however, how active genes marked with
H3K4me3 can be hypermethylated in cancer cells.
H3K4me3-marked genes are largely protected from
DNA methylation in ES cells since DNMT3L recruits
de novo DNMTs to genomic regions devoid of
H3K4me3 modiﬁcations (5), but an increase in DNA
methylation is detected with the loss of H3K4 methylation
during differentiation (36). Okitsu et al. (37) reported that
DNA methylation plays a role in the exclusion of H3K4
methylation and leads to gene silencing. Here, we show
that overexpression of DNMT3A1 or DNMT3B1 could
induce de novo DNA methylation at different histone-
marked loci, suggesting a possible mechanism for how
H3K4me3- or H3K27me3-marked loci could acquire
DNA methylation.
Figure 5. Continued
and H3K27me3) showed that speciﬁc target genes of DNMT3A1 are associated with H3K4me3 modiﬁcations, whereas the speciﬁc target genes of
DNMT3B1 are associated with H3K27me3. The total represents the percentage of histone modiﬁcations for all 808 genes. Overlapping target genes
and speciﬁc target genes of DNMTs are shown Figure 5A. The association between de novo methylated sites and histone marks was calculated using
a Chi-squared test. (C) Validation of the association between DNA methylation and histone modiﬁcations. Chromatin from HEK 293T cells was
immunoprecipitated using antibodies against H3K4me3, H3K27me3 or H3K9me3 and analyzed by real-time PCR for 20 loci that showed the
greatest increase in de novo DNA methylation changes speciﬁc for DNMT3A1 (left 10 loci) and DNMT3B1 (right 10 loci). The increase in DNA
methylation was calculated by the difference in the  -value between mock vector-transfected cell lines and DNMT3A1- or DNMT3B1-transfected cell
lines. ChIP-on-chip histone data are shown as K4: H3K4me3, K27: H3K27me3, Bi: H3K4me3/H3K27me3, and N: neither H3K4me3 nor
H3K27me3. ChIP data represent the means±SD. of three independent experiments. The white bar represents the IgG control, and the black
bar represents enrichment of histone modiﬁcations. All data were converted to relative values based on a standard curve and normalized to 1% input
values. Real-time PCR primers for 20 loci were designed within ±500bp at the CpG sites analyzed in the Illumina DNA methylation assay, except
the HS3ST2 genes (+1359bp). See details for the primers in Supplementary Table S1.
114 Nucleic Acids Research, 2011,Vol. 39,No. 1It is important to underscore that de novo DNA methy-
lation targeting by DNMT3A1 and DNMT3B1 was not
absolutely associated with H3K4me3 and H3K27me3, re-
spectively. Clearly, genes that are associated with
H3K4me3 could be de novo methylated by DNMT3B1
and the opposite was true as well. Although it is attractive
to think of DNMT targeting to speciﬁc histone marks, it is
also possible that other factors such as transcriptionally
active versus inactive sites could be the determining factor.
We attempted to delineate the relationship of DNMT3A1
and DNMT3B1 with either histone mark or transcription
by performing global ChIP-on-chip experiments and
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Figure 6. Changes in mRNA expression and histone modiﬁcation by overexpression of DNMT3A1 and DNMT3B1. Number of downregulated
(>2-fold) genes in DNMT3A1- and DNMT3B1-overexpressing cells. The number of downregulated genes in whole genome mRNA representing 8276
transcripts (A) and in the 808 genes studied for DNA methylation (B). (C) Changes in mRNA expression and histone modiﬁcation. Real-time PCR
to measure the mRNA expression of DNMT3A1 target genes (EYA4 and HOXA11) and DNMT3B1 target genes (IGF2AS and CDH11), and ChIP
combined with real-time PCR for histone medications (H3K4me3, H3K27me3 and H3K9me3) in HEK 293T cells (white bar), DNMT3A1 cells
(black bar) and DNMT3B1 cells (gray bar). Real-time RT-PCR and ChIP data represent the means±SD. For mRNA expression, the primer
efﬁciency for all four genes was  95%, and comparison of the fold changes of the standard curve was consistent with the Ct-calculated fold
changes. (t-test; *P<0.05 and ***P<0.001 versus HEK 293T cells).
Nucleic AcidsResearch, 2011, Vol.39,No. 1 115comparingto expression arrayproﬁles; however, due to the
tight association of H3K4me3 with transcriptionally active
and H3K27me3 with inactive genes, we were unable to de-
termine the exact mechanism of targeting in this work.
It remains to be seen whether these DNA methylation
patterns shown in our cell model system can occur in ES
cells and primary tumor tissues. Unique cellular environ-
ments in different cell types might generate DNA methy-
lation patterns that differ from those observed in our
studies. For example, DNMT3L-deﬁcient female mice
show DNA methylation defects in maternally imprinted
genes, but DNMT3L-deﬁcient male germ cells abolish the
methylation of interspersed DNA repeats (6,7). The
bivalent chromatin structure and the unique expression
patterns of DNMTs might provide a different environ-
ment for de novo DNA methylation in ES cells. Another
limitation of our cell model system is that target sites
already methylated by endogenous DNMTs could not
be identiﬁed. Nonetheless, the importance of the
observed DNA methylation changes might be directly
translatable to the epigenetic changes found in cancer
and in other diseases. In the present study, de novo
methylated genes by different DNMTs coincided with
genes that are known to be aberrantly methylated in dif-
ferent types of cancer (Supplementary Table S7). Of the
397 de novo methylated genes, 84 are known to be aber-
rantly hypermethylated in cancer (http://www.pubmeth
.org/). Aberrant DNA methylation via overexpression of
DNMT isoforms or changes in DNMT isoform expression
patterns could also reﬂect an important cancer mechanism.
The expression of DNMT3A1 and DNMT3B1 is low in
normal tissues, but the expression of DNMT3B isoforms
is signiﬁcantly increased in cancer (15,38). DNMT3B
isoforms are the predominant forms of DNMT3B ex-
pressed in human lung cancer, and one of these isoforms,
DNMT3B4, is responsible for promoter-speciﬁc methy-
lation of RASSF1A in an NSCLC cell line (14). Recent
studies have shown that overexpression of Dnmt3b in con-
junction with Apc gene mutations promotes tumorigenesis
in mice (10). It is possible that speciﬁc aberrant DNA
methylation patterns are associated with the over-
expression of speciﬁc DNMT isoforms detected in different
types of cancer.
We believe our model system can be used as a valuable
tool to understand how different DNMT isoforms are
involved in establishing normal and aberrant DNA
methylation patterns. Using this system, we demonstrated
that overexpression of DNMT isoforms induces aberrant
de novo DNA methylation at speciﬁc loci, and analysis of
these de novo targets revealed that DNMT isoforms have
speciﬁc genomic preferences, possibly directed by histone
modiﬁcations. The knowledge that DNMT isoforms can
have speciﬁc genomic targets based on speciﬁc isoform
domains and histone medications suggests a possible
mechanism by which normal and abnormal DNA methy-
lation patterns are established.
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Figure 7. Changes in DNA methylation target sites of DNMT isoforms in the absence of speciﬁc DNMT domains. DNA methylated loci were
compared between DNMT isoforms that were identical, with the exception that they lacked speciﬁc domains. (A) DNMT3B exon10, (B) DNMT3B
PWWP, (C) N-terminus of DNMT3A or DNMT3B and (D) both DNMT3B PWWP and the N-terminus. The association between de novo
methylated loci and histone marks was calculated using a Chi-squared test; *P<0.05 and **P<0.01. All genes are listed in Supplementary
Table S6.
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